Search
TA-CIN
go.drugbank.com/drugs/DB05809InvestigationalTA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
Insulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalCompared to human insulin, it has a single amino acid substitution at position B28 where proline is replaced with aspartic acid. … Due to its duration of action of around 5 hours, NovoRapid is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from
Categories: Drugs Used in DiabetesProducts: NovoRapid FlexPen 100U/ml solution for injection in pre-filled pen, RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/mlCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available. … [A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase
Categories: Compounds used in a research, industrial, or household settingBalsalazide
go.drugbank.com/drugs/DB01014ApprovedThe chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt. … Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK.
Synonyms: (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid, (E)-5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acidRemibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalThe FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.
Rucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigational[A249240] The drug was later approved by the European Commission in May 2018.[L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]. … [A18745] Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality.
Colfosceril palmitate
go.drugbank.com/drugs/DB09114ApprovedWithdrawn[A31510] It was part of the first generation of commercially available artificial surfactants.[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990. … Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome.
Garetosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic … [L63940,L64047] It is the second therapy approved for FOP, following [palovarotene] (Sohonos), which was approved in 2023, and is the first FOP therapy shown to reduce clinician-assessed flare-ups.
Antithrombin Alfa
go.drugbank.com/drugs/DB11166ApprovedAntithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations
Sotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigationalfound to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L41369] Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.[L39625,L39620]